An open-label, multi-center, dose-escalation Phase Ib study to determine the recommended phase 2 dose of APN401 in patients with advanced solid tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504281-34-00

Acronym

APN401-104

Enrollment

Registered

2023-07-24

Start date

2023-08-22

Completion date

2024-11-20

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026